Thermo Fisher Scientific, the world’s leading provider of laboratory instruments with more than $40 billion in annual revenue, has entered a multi-year collaboration with NVIDIA to integrate the NVIDIA AI platform into scientific instrumentation and lab automation. Under the agreement, Thermo Fisher will embed NVIDIA DGX Spark™ supercomputing nodes and leverage pretrained models such as NeMo™ and BioNeMo™ to enable real-time sample preparation, instrument control and data analysis. The partnership targets a 50% reduction in manual workflows and a 30% increase in throughput across genomics, proteomics and clinical diagnostics laboratories by 2027, helping customers accelerate experimental design, sample processing and result interpretation at industrial scale.

At CES 2026, NVIDIA announced that its Rubin platform—composed of six new AI-optimized chips—has entered full production and will begin customer deliveries in the second half of the year. Rubin promises up to 90% lower cost per token for inference workloads compared with the current Blackwell generation, and benchmarks indicate a 3× improvement in throughput for large-language model training. NVIDIA projects that combined Rubin and Blackwell system sales will reach approximately $500 billion in 2026, a near threefold increase over its trailing-12-month revenue of $187 billion, driven by deployments at hyperscale cloud providers and enterprise data centers worldwide.

Analysts note that while NVIDIA currently trades at roughly 40 times calendar-year 2025 earnings, its forward multiple based on earnings forecasts for 2035 is closer to 8, implying potential share-price appreciation of 200–500% over the next decade. This valuation gap reflects NVIDIA’s rapidly expanding presence beyond GPUs into AI-powered drug discovery partnerships, robotics, autonomous vehicles and industrial automation. Consensus estimates call for year-over-year revenue growth to exceed 65% in the fourth quarter of fiscal 2026, and more than a dozen brokerage firms maintain a Buy rating, citing a structural shift toward AI-native research and manufacturing workflows.

Beyond hardware, NVIDIA is deepening its software and services ecosystem through partnerships with leading life-sciences and industrial players. The collaboration with Thermo Fisher complements alliances with Eli Lilly in AI-driven drug discovery, while agreements with OEMs such as Caterpillar and Archer Aviation integrate NVIDIA’s Thor IGX platform into autonomous heavy machinery and electric vertical takeoff and landing aircraft. By connecting instruments, data pipelines and AI compute in a unified stack, NVIDIA cements its role as the de facto enabler of the ‘lab-in-the-loop’ and ‘factory-of-the-future’ paradigms, reinforcing barriers to entry for competing chipmakers and software providers.